Hansa Biopharma
Sweden - Lund
PharmaceuticalFocus: Novel immunomodulatory enzymes for transplantation and acute autoimmune diseases
Hansa Biopharma is a life sciences company focused on Novel immunomodulatory enzymes for transplantation and acute autoimmune diseases.
Immunology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Imlifidase
Kidney Transplant RejectionClinical Trials (1)
NCT04711850An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
N/AImlifidase administered in the ConfIdeS study
Kidney Transplantation in Highly Sensitized PatientsClinical Trials (1)
NCT05714514Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
N/AImlifidase
Kidney Transplant Failure and RejectionClinical Trials (1)
NCT03611621A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
N/Adelandistrogene moxeparvovec
Duchenne Muscular DystrophyClinical Trials (1)
NCT06241950A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
Phase 1IdeS
HealthyClinical Trials (1)
NCT01802697Safety Study on IdeS in Healthy Volounteers
Phase 1IdeS®
Renal DiseaseClinical Trials (1)
NCT02426684Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
Phase 1/2Imlifidase
Guillain-Barré Syndrome (GBS)Clinical Trials (1)
NCT03943589A Study of Imlifidase in Patients With Guillain-Barré Syndrome
Phase 2Phase 2
Clinical Trials (1)
NCT03157037Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
Phase 2Imlifidase
Crigler-Najjar SyndromeClinical Trials (1)
NCT06518005Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
Phase 2Phase 2
Clinical Trials (1)
NCT02854059IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
Phase 2Phase 2
Clinical Trials (1)
NCT02790437A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
Phase 2Phase 2
Clinical Trials (1)
NCT02475551Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation
Phase 2Phase 2
Clinical Trials (1)
NCT02224820Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
Phase 2Imlifidase
Kidney Transplant RejectionClinical Trials (1)
NCT03897205An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
Phase 2Phase 2
Clinical Trials (1)
NCT05049850A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
Phase 2Phase 2
Clinical Trials (1)
NCT05753930Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
Phase 2Phase 3
Clinical Trials (1)
NCT05369975Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Phase 3Phase 3
Clinical Trials (1)
NCT04935177Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
Phase 3Phase 3
Clinical Trials (1)
NCT05679401A Study With Imlifidase in Anti-GBM Disease
Phase 3Imlifidase administered in the 20-HMedIdeS-19
Long Term Efficacy and SafetyClinical Trials (1)
NCT05937750A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 20 clinical trials